According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.84554. At the end of 2022 the company had a P/S ratio of 1.85.
Year | P/S ratio | Change |
---|---|---|
2022 | 1.85 | -21.36% |
2021 | 2.35 | 11.79% |
2020 | 2.10 | -22.19% |
2019 | 2.70 | 17.15% |
2018 | 2.31 | 3.51% |
2017 | 2.23 | -12.8% |
2016 | 2.55 | -6.69% |
2015 | 2.74 | -1.16% |
2014 | 2.77 | -10.25% |
2013 | 3.09 | 23.35% |
2012 | 2.50 | -5.99% |
2011 | 2.66 | 13.69% |
2010 | 2.34 | -4.53% |
2009 | 2.45 | 10.57% |
2008 | 2.22 | -27.13% |
2007 | 3.04 | -13.47% |
2006 | 3.52 | -7.68% |
2005 | 3.81 | 1.99% |
2004 | 3.73 | -2.38% |
2003 | 3.83 | -13.88% |
2002 | 4.44 | -28.97% |
2001 | 6.25 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | 3.72 | 101.54% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 2.25 | 21.90% | ๐บ๐ธ USA |
![]() Sanofi SNY | 2.84 | 53.97% | ๐ซ๐ท France |
![]() Merck MRK | 4.52 | 144.86% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 4.79 | 159.79% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | 0.6520 | -64.67% | ๐ฎ๐ฑ Israel |
![]() Dynavax Technologies
DVAX | 1.72 | -6.56% | ๐บ๐ธ USA |